CORRECTION

Error in Figure: In the Original Investigation titled “Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies,”1 published in the February 2020 issue, the y-axis was incorrect in the Figure. The data should span 87% to 100% rather than 15% to 100%. This article has been corrected online.